Cel Sci (CVM) Free Cash Flow (2010 - 2026)
Cel Sci (CVM) posted Free Cash Flow of -$4.0 million for Q1 2026, little changed sequentially from -$4.0 million in Q4 2025, and up 7.95% YoY from -$3.7 million in Q1 2025.
Cel Sci (CVM) Free Cash Flow (2010 - 2026) Analysis & Trends
Cel Sci has reported Free Cash Flow for 16 years, with the latest figure at -$4.0 million in Q1 2026.
- Quarterly Free Cash Flow rose 7.95% year-over-year to -$4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.7 million (up 7.35% YoY) and the FY2025 annual result came in at -$17.2 million, up 9.25% from the prior year.
- Free Cash Flow held at -$4.0 million in Q1 2026 per CVM's latest filing, from -$4.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$3.3 million in Q1 2022 and troughed at -$7.6 million in Q1 2023.
- A 5-year average of -$4.8 million and a median of -$4.7 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow soared 61.29% in 2022, then sank 132.2% in 2023.
- Over 5 years, Free Cash Flow stood at -$4.7 million in 2022, then retreated by 4.65% to -$4.9 million in 2023, then increased by 15.52% to -$4.2 million in 2024, then increased by 3.61% to -$4.0 million in 2025, then dropped by 0.01% to -$4.0 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$4.0 million, -$4.0 million, and -$4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | -4.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.02 Mn |
| Mar 31, 2026 | -4.02 Mn |
| Dec 31, 2025 | -4.02 Mn |
| Dec 31, 2025 | -4.02 Mn |
| Sep 30, 2025 | -4.68 Mn |
| Sep 30, 2025 | -4.68 Mn |
| Jun 30, 2025 | -3.94 Mn |
| Jun 30, 2025 | -3.94 Mn |
| Mar 31, 2025 | -4.37 Mn |
| Mar 31, 2025 | -4.37 Mn |
| Dec 31, 2024 | -4.17 Mn |
| Dec 31, 2024 | -4.17 Mn |
| Sep 30, 2024 | -4.84 Mn |
| Sep 30, 2024 | -4.84 Mn |
| Jun 30, 2024 | -4.60 Mn |
| Jun 30, 2024 | -4.60 Mn |
| Mar 31, 2024 | -4.53 Mn |
| Mar 31, 2024 | -4.53 Mn |
| Dec 31, 2023 | -4.94 Mn |
| Dec 31, 2023 | -4.94 Mn |